Skip to content
BOLTBolt Biotherapeutics, Inc.

Earnings

When Bolt Biotherapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

27 quarters. Mar 31, 2020 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 11, after the close

Thu, Mar 11, 2027in 113 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 19 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$2.50M
Revenue, change from a year earlier: Q3 2026 −100.0%, Q2 2026 −99.7%, Q1 2026 −97.9%, Q4 2025 n/m
Net income
-$6.63M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$0.00−100.0% vs Q3 2025

Latest results

  1. Q3 2026Nov 12, 2026, after the closeThe release
    Revenue
    $0.00
    −100.0%
    Net income
    -$4.42M
    N/M
    EPS
    -$2.25
    N/M
    In October, Bolt completed its acquisition of Prana Therapies in a sign-and-close, stock-for-stock reverse merger and closed a concurrent $120 million private placement financing with leading healthcare institutional investors.
  2. Q2 2026Aug 11, 2026, after the closeThe release16.0%by the close of Aug 12
    Revenue
    $5.00K
    −99.7%
    Net income
    -$7.46M
    N/M
    EPS
    -$3.88
    N/M
  3. Q1 2026May 12, 2026, after the closeThe release0.5%by the close of May 13
    Revenue
    $26.00K
    −97.9%
    Net income
    -$7.67M
    N/M
    EPS
    -$3.99
    N/M
  4. Q4 2025Mar 12, 2026, after the closeThe release+5.9%by the close of Mar 16
    Revenue
    $2.50M
    —
    Net income
    -$6.63M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 12, 2026 · after-hoursNov 13, 202644 d10-Q$0.00−100.0%-$2.25—
Q2 2026Jun 30, 2026Aug 11, 2026 · after-hoursAug 11, 202642 d10-Q$5.00K−99.7%-$3.8816.0%
Q1 2026Mar 31, 2026May 12, 2026 · after-hoursMay 12, 202642 d10-Q$26.00K−97.9%-$3.990.5%
FY 2025
Q4 2025derivedDec 31, 2025Mar 12, 2026 · after-hoursMar 12, 202671 d10-K$2.50M——+5.9%
Q3 2025Sep 30, 2025Nov 12, 2025 · after-hoursNov 12, 202543 d10-Q$2.17M+90.1%-$3.721.0%
Q2 2025Jun 30, 2025Aug 14, 2025 · after-hoursAug 14, 202545 d10-Q$1.80M+41.5%-$4.465.3%
Q1 2025Mar 31, 2025May 12, 2025 · after-hoursMay 12, 202542 d10-Q$1.22M−76.8%-$5.764.2%
FY 2024
Q4 2024derivedDec 31, 2024Mar 24, 2025 · after-hoursMar 24, 202583 d10-K$0.00−100.0%——
Q3 2024Sep 30, 2024Nov 12, 2024 · after-hoursNov 12, 202443 d10-Q$1.14M−54.9%-$7.93—
Q2 2024Jun 30, 2024Aug 13, 2024 · after-hoursAug 13, 202444 d10-Q$1.28M−11.0%-$11.12—
Q1 2024Mar 31, 2024—May 14, 202444 d10-Q$5.27M+188.8%-$0.28—
Earlier years, FY 2020 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 13, 2026458877
10-QAug 11, 2026344597
10-QMay 12, 2026219382
10-KMar 12, 2026104121
10-QNov 12, 2025277549
10-QAug 14, 2025000007
10-QMay 12, 2025069188
10-KMar 24, 2025043873
10-QNov 12, 2024125413
10-QAug 13, 2024096200

Provenance

ProvenanceData status and checks

Bolt Biotherapeutics, Inc. · CIK 1641281 · Engraved from SEC EDGAR